Trial · NCT01262677
Results by group414
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 414
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase | Pregabalin 165 mg | Baseline | 2.24 | Standard Deviation 0.757 | ln (seizures per 28 days) |
| Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase | Pregabalin 330 mg | Baseline | 2.33 | Standard Deviation 0.873 | ln (seizures per 28 days) |
| Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase | Placebo | Baseline | 2.32 | Standard Deviation 0.910 | ln (seizures per 28 days) |
| Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase | Pregabalin 165 mg | Week 14 | 1.84 | Standard Deviation 1.003 | ln (seizures per 28 days) |
| Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase | Pregabalin 330 mg | Week 14 | 1.80 | Standard Deviation 1.030 | ln (seizures per 28 days) |
| Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase | Placebo | Week 14 | 1.93 | Standard Deviation 1.132 | ln (seizures per 28 days) |
| Percentage of Participants With a ≥50% Reduction in the 28-day Partial Seizure Rate From Baseline During the Double-blind Treatment Phase | Pregabalin 165 mg | Responder | 37.8 | percentage of participants | |
| Percentage of Participants With a ≥50% Reduction in the 28-day Partial Seizure Rate From Baseline During the Double-blind Treatment Phase | Pregabalin 330 mg | Responder | 45.9 | percentage of participants | |
| Percentage of Participants With a ≥50% Reduction in the 28-day Partial Seizure Rate From Baseline During the Double-blind Treatment Phase | Placebo | Responder | 35.8 | percentage of participants | |
| Percentage of Participants With a ≥50% Reduction in the 28-day Partial Seizure Rate From Baseline During the Double-blind Treatment Phase | Pregabalin 165 mg | Non-responder | 62.2 | percentage of participants | |
| Percentage of Participants With a ≥50% Reduction in the 28-day Partial Seizure Rate From Baseline During the Double-blind Treatment Phase | Pregabalin 330 mg | Non-responder | 54.1 | percentage of participants | |
| Percentage of Participants With a ≥50% Reduction in the 28-day Partial Seizure Rate From Baseline During the Double-blind Treatment Phase | Placebo | Non-responder | 64.2 | percentage of participants | |
| Percentage Change From Baseline in 28-day Partial Seizure Rate During the Double-blind Treatment Phase | Pregabalin 165 mg | -15.00 | Standard Error 11.668 | ln (seizures per 28 days) | |
| Percentage Change From Baseline in 28-day Partial Seizure Rate During the Double-blind Treatment Phase | Pregabalin 330 mg | -31.54 | Standard Error 10.772 | ln (seizures per 28 days) | |
| Percentage Change From Baseline in 28-day Partial Seizure Rate During the Double-blind Treatment Phase | Placebo | -5.70 | Standard Error 10.918 | ln (seizures per 28 days) | |
| Frequency of Secondary Generalized Tonic-clonic Seizures (SGTC) During the Double-blind Treatment Phase | Pregabalin 165 mg | 3.99 | Standard Deviation 8.667 | seizures per 28 days | |
| Frequency of Secondary Generalized Tonic-clonic Seizures (SGTC) During the Double-blind Treatment Phase | Pregabalin 330 mg | 4.43 | Standard Deviation 14.736 | seizures per 28 days | |
| Frequency of Secondary Generalized Tonic-clonic Seizures (SGTC) During the Double-blind Treatment Phase | Placebo | 7.51 | Standard Deviation 24.979 | seizures per 28 days | |
| Log Transformed 28-day SGTC Rate for All SGTCs During the Double-blind Maintenance Phase | Pregabalin 165 mg | 0.46 | Standard Error 0.049 | ln (seizures per 28 days) | |
| Log Transformed 28-day SGTC Rate for All SGTCs During the Double-blind Maintenance Phase | Pregabalin 330 mg | 0.48 | Standard Error 0.045 | ln (seizures per 28 days) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01262677/results